ADVERTISEMENT
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Uta Mommert contributed 234 entries already.
Which European Biotechnology news stories topped the charts this year? The European Biotechnology team delved into archives and analysed the click statistics. And here they are: the most wanted news stories of 2016!
Contaminated blood can transmit prion disease even if the donor does not yet show any symptoms. A new blood test could make the blood supply safer. Two reports show it can correctly diagnose Variant Creutzfeldt-Jakob disease – with 100% certainty.
French immunotherapy expert Neovacs has teamed up with CDMO 3P Biopharmaceuticals for the manufacture of interferon alpha with recently licensed technology.
UK-based biopharma group Kymab has brought a new backer from China on board. With the help from ORI Healthcare Fund, Kymab secured a US$100m Series C financing.
Pharmatio GmbH, already established in the monitoring and site liaison of clinical trials, has restructured its services. With Clinical Trial Liaison, the sponsors of clinical trials can ensure the patient recruitment and effectiveness of their clinical trials. The Clinical Trial Task Force masters difficult or unforeseen challenges in clinical trials, and High Quality Monitoring ensures that Pharmatio ensures all-time inspection readiness of clinical trial sites.
Investors are once again flocking to back biotechs in Europe. Belgian Life Sciences fund Fund+ has raised €125m – a quarter more than initially anticipated.
Part microbe, part machine: cyborg bacteria developed at ETH Zurich could revolutionise the biotechnological production of molecules. The bacteria have been engineered to respond to light signals.
New name, new outlook: blood disorder specialist Dilaforette will be known as Modus Therapeutics Holding from here on out. The Swedish company also announced an intention to float in the near future.